Eilean Therapeutics
Clinical trials sponsored by Eilean Therapeutics, explained in plain language.
-
New drug ZE74-0282 targets rare blood cancers in early trial
Disease control Not yet recruitingThis early-phase study tests an experimental drug, ZE74-0282, in about 60 adults with polycythemia vera or myelofibrosis caused by a JAK2 V617F mutation. The main goals are to find the safest dose and see if the drug shows signs of fighting the disease. Participants will take the…
Phase: PHASE1 • Sponsor: Eilean Therapeutics • Aim: Disease control
Last updated May 26, 2026 06:21 UTC
-
New hope for advanced cancer patients: experimental drug ZE94-0605 enters first human trial
Disease control Not yet recruitingThis early-phase study tests an experimental drug called ZE94-0605 in about 60 adults with advanced solid tumors that have not responded to or are not eligible for standard treatments. The main goals are to find the safest dose and to see if the drug can shrink tumors. The study …
Phase: PHASE1 • Sponsor: Eilean Therapeutics • Aim: Disease control
Last updated May 22, 2026 13:50 UTC